Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

NCT00496652 is registered in ClinicalTrials.gov with Danish Head and Neck Cancer Group as lead sponsor.

NCT NCT00496652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00496652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Danish Head and Neck Cancer Group
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2007
Completion date
November 30, 2016
Enrollment
619 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the head and neck